Article
CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation.
Basic & clinical pharmacology & toxicology - 1 Sept 2018
Hu Rong, Barratt Daniel T, Coller Janet K, Sallustio Benedetta C, Somogyi Andrew A
Abstract excerpt
Tacrolimus (TAC) is a first-line immunosuppressant used to prevent organ rejection after kidney transplantation. There is large inter-individual variability in its pharmacokinetics. Single nucleotide polymorphisms (SNPs) in genes encoding TAC metabolizing enzymes cytochromes P450 3A4/5 (CYP3A4/5), P-glycoprotein efflux transporter (ABCB1), their expression regulator pregnane X receptor (NR1I2) and CYP3A co-factor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
